Risk factors for mortality caused by pseudomonas aeruginosa infection in hospitalized patients with oncologic diagnosis in three cities of Colombia

Pseudomonas aeruginosa es una bacteria oportunista Gram negativa particularmente eficiente en la adquisición de mecanismos de resistencia y de alta prevalencia en infecciones nosocomiales en pacientes oncológicos. Objetivo: identificar los factores de riesgo para mortalidad en pacientes oncológicos con aislamiento de P. aeruginosa. Metodología: estudio descriptivo, la población de estudio fueron los casos reportados con aislamiento de P. aeruginosa en el servicio de hospitalización de Oncólogos de Occidente en Pereira, Armenia y Manizales durante el año 2015. Se realizaron análisis univariados y multivariados; la supervivencia se estableció según el método de Kaplan-Meier. Se estableció un valor de p <0.05. Se usó el software STATA. Se tuvo aval de bioética de la Universidad Tecnológica de Pereira. Resultados: se estudió 41 casos confirmados de cultivos positivos de P. aeruginosa. El sexo masculino (46.3%), anemia (46.3%), neutropenia febril (41%), trombocitopenia (29.3%) y haber sido hospitalizado en la unidad de cuidados intensivos (29.3%) fueron asociados estadísticamente con mayor mortalidad (p=0.019); con estos resultados se diseñó una escala de riesgo (alfa de Cronbach =0.72). Los pacientes con cuatro de estas exposiciones mostraron mayor riesgo de mortalidad al egreso hospitalario con una sensibilidad del 68% y especificidad del 90%. La P. aeruginosa presentó resistencia a cefepime (36.6%) y a aztreonam (34.1%), mientras que la letalidad global fue del 26.8%. Conclusión: El sexo masculino, la coexistencia de anemia, trombocitopenia, y neutropenia febril, así como la estancia en la unidad de cuidados intensivos aumentan la mortalidad en los pacientes oncológicos infectados con P. aeruginosa.Pseudomonas aeruginosa is a Gram-negative and rod-shape opportunistic bacterium that is particularly efficient in the acquisition of resistance mechanisms and its high prevalence in nosocomial infections in cancer patients. Objective: To identify risk factors for mortality in cancer patients with P. aeruginosa infection. Methodology: A descriptive study was carried out in patients with P. aeruginosa infection during the hospitalization service of “Oncólogos de Occidente” in Pereira, Armenia and Manizales during 2015. Univariate and multivariate analyzes were performed. The survival analysis was established according to the Kaplan-Meier method. A value of p<0.05 was established for it. The analyses were examined with the STATA software. This study was endorsed by the bioethics committee of the “Universidad Tecnológica de Pereira”. Results: Fourty-one patients with positive culture for P. aeruginosa were studied. Males (46.3%), anemia (46.3%), febrile neutropenia (41%), thrombocytopenia (29.3%) and previous hospitalization in an intensive care unit (29.3%) were associated with higher mortality risk (p = 0.019); a risk scale was designed with these factors (Cronbach´s alpha = 0.72). Patients who presented four of these exposures were at higher risk of mortality with a sensitivity of 68% and specificity of 90% at the moment of discharge. P. aeruginosa showed 36.6% of resistance to cefepime, 34.1% to aztreonam, the mortality rate was 26.8%. Conclusion: Male sex, anemia, thrombocytopenia, febrile neutropenia and previous hospitalization in an intensive care unit increase the mortality rate in patients with cancer who were infected by P. aeruginosa.

Falla cardíaca avanzada en pacientes tratados con dispositivos electrofisiológicos en una unidad de electrofisología, Pereira (Colombia)

Introduction: advanced heart failure it's a disease with a high prevalence in the world wide,with an increasing mortality and hospitalization rates, due to his severity and clinical profile. Which costs to the health system is up to 20% of the resources devoted to the management of cardiovascular disease in North Amerca. A cross-sectional study was made with 70 patients on pharmacological treatment and Cardiac Resynchronization Therapy with or without Implantable Cardioverter (CDI) or Implantable Cardioverter (CDI) among 2010 and 2012.Methods: a cross-sectional study.Results: we found 71% with hypertension, 65,75% ischemic cardiopathy , 58.3% with resynchronizator with or without CDI, 90% had two or more drugs for heart failure, 77% had beta blocker, 90% ACE inhibitor or ARB, 85.7% diuretics.Conclusion: patients with advanced heart failure who underwent electrophysiological therapy, were clinically characterized in Pereira, Colombia.Resumen: la falla cardíaca avanzada es una enfermedad prevalente, con una tasa alta de mortalidad y hospitalización con relación a su estadio y perfil clínico, que cuesta en Norteamérica hasta el 20% de los recursos destinados para el manejo de la enfermedad cardiovascular. Se realizó un análisis transversal a una cohorte de 70 pacientes en tratamiento farmacológico y cardioresincronizador con o sin cardiodesfibirlador, o solo cardiodesfibrilador automático (ICD) implantado entre los años 2010 y 2012.Métodos: el presente es un estudio transversal.Resultados: 71% presentaron hipertensión arterial HTA; 65,75% cardiopatía isquémica, siendo el 58.3% portadores de resincronizador con o sin cardiodesfibrilador. El 90% de los pacientes tiene 2 o más medicamentos, 77% betabloqueador, 90% iECA o ARA II, 85.7% algún diurético.Conclusión: se caracterizaron los pacientes que recibieron terapia electrofisiológica para manejo avanzado de falla cardíaca.ardíaca

Factores de riesgo para mortalidad en la infección por Pseudomonas aeruginosa en pacientes oncológicos hospitalizados en tres ciudades de Colombia

Introduction: Pseudomonas aeruginosa is a Gram-negative and rod-shape opportunistic bacterium that is particularly efficient in the acquisition of resistance mechanisms and its high prevalence in nosocomial infections in cancer patients. Objective: To identify risk factors for mortality in cancer patients with P. aeruginosa infection. Methodology: A descriptive study was carried out in patients with P. aeruginosa infection during the hospitalization service of “Oncólogos de Occidente” in Pereira, Armenia and Manizales during 2015. Univariate and multivariate analyzes were performed. The survival analysis was established according to the Kaplan-Meier method. A value of p<0.05 was established for it. The analyses were examined with the STATA software. This study was endorsed by the bioethics committee of the “Universidad Tecnológica de Pereira”. Results: Fourty-one patients with positive culture for P. aeruginosa were studied. Males (46.3%), anemia (46.3%), febrile neutropenia (41%), thrombocytopenia (29.3%) and previous hospitalization in an intensive care unit (29.3%) were associated with higher mortality risk (p = 0.019); a risk scale was designed with these factors (Cronbach´s alpha = 0.72). Patients who presented four of these exposures were at higher risk of mortality with a sensitivity of 68% and specificity of 90% at the moment of discharge. P. aeruginosa showed 36.6% of resistance to cefepime, 34.1% to aztreonam, the mortality rate was 26.8%. Conclusion: Male sex, anemia, thrombocytopenia, febrile neutropenia and previous hospitalization in an intensive care unit increase the mortality rate in patients with cancer who were infected by P. aeruginosa. Introducción: Pseudomonas aeruginosa es una bacteria oportunista Gram negativa particularmente eficiente en la adquisición de mecanismos de resistencia y de alta prevalencia en infecciones nosocomiales en pacientes oncológicos. Objetivo: identificar los factores de riesgo para mortalidad en pacientes oncológicos con aislamiento de P. aeruginosa. Metodología: estudio descriptivo, la población de estudio fueron los casos reportados con aislamiento de P. aeruginosa en el servicio de hospitalización de Oncólogos de Occidente en Pereira, Armenia y Manizales durante el año 2015. Se realizaron análisis univariados y multivariados; la supervivencia se estableció según el método de Kaplan-Meier. Se estableció un valor de p <0.05. Se usó el software STATA. Se tuvo aval de bioética de la Universidad Tecnológica de Pereira. Resultados: se estudió 41 casos confirmados de cultivos positivos de P. aeruginosa. El sexo masculino (46.3%), anemia (46.3%), neutropenia febril (41%), trombocitopenia (29.3%) y haber sido hospitalizado en la unidad de cuidados intensivos (29.3%) fueron asociados estadísticamente con mayor mortalidad (p=0.019); con estos resultados se diseñó una escala de riesgo (alfa de Cronbach =0.72). Los pacientes con cuatro de estas exposiciones mostraron mayor riesgo de mortalidad al egreso hospitalario con una sensibilidad del 68% y especificidad del 90%. La P. aeruginosa presentó resistencia a cefepime (36.6%) y a aztreonam (34.1%), mientras que la letalidad global fue del 26.8%. Conclusión: El sexo masculino, la coexistencia de anemia, trombocitopenia, y neutropenia febril, así como la estancia en la unidad de cuidados intensivos aumentan la mortalidad en los pacientes oncológicos infectados con P. aeruginosa

The Genome of a Pathogenic Rhodococcus: Cooptive Virulence Underpinned by Key Gene Acquisitions

We report the genome of the facultative intracellular parasite Rhodococcus equi, the only animal pathogen within the biotechnologically important actinobacterial genus Rhodococcus. The 5.0-Mb R. equi 103S genome is significantly smaller than those of environmental rhodococci. This is due to genome expansion in nonpathogenic species, via a linear gain of paralogous genes and an accelerated genetic flux, rather than reductive evolution in R. equi. The 103S genome lacks the extensive catabolic and secondary metabolic complement of environmental rhodococci, and it displays unique adaptations for host colonization and competition in the short-chain fatty acid–rich intestine and manure of herbivores—two main R. equi reservoirs. Except for a few horizontally acquired (HGT) pathogenicity loci, including a cytoadhesive pilus determinant (rpl) and the virulence plasmid vap pathogenicity island (PAI) required for intramacrophage survival, most of the potential virulence-associated genes identified in R. equi are conserved in environmental rhodococci or have homologs in nonpathogenic Actinobacteria. This suggests a mechanism of virulence evolution based on the cooption of existing core actinobacterial traits, triggered by key host niche–adaptive HGT events. We tested this hypothesis by investigating R. equi virulence plasmid-chromosome crosstalk, by global transcription profiling and expression network analysis. Two chromosomal genes conserved in environmental rhodococci, encoding putative chorismate mutase and anthranilate synthase enzymes involved in aromatic amino acid biosynthesis, were strongly coregulated with vap PAI virulence genes and required for optimal proliferation in macrophages. The regulatory integration of chromosomal metabolic genes under the control of the HGT–acquired plasmid PAI is thus an important element in the cooptive virulence of R. equi

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Effectiveness of an intervention for improving drug prescription in primary care patients with multimorbidity and polypharmacy:Study protocol of a cluster randomized clinical trial (Multi-PAP project)

This study was funded by the Fondo de Investigaciones Sanitarias ISCIII (Grant Numbers PI15/00276, PI15/00572, PI15/00996), REDISSEC (Project Numbers RD12/0001/0012, RD16/0001/0005), and the European Regional Development Fund ("A way to build Europe").Background: Multimorbidity is associated with negative effects both on people's health and on healthcare systems. A key problem linked to multimorbidity is polypharmacy, which in turn is associated with increased risk of partly preventable adverse effects, including mortality. The Ariadne principles describe a model of care based on a thorough assessment of diseases, treatments (and potential interactions), clinical status, context and preferences of patients with multimorbidity, with the aim of prioritizing and sharing realistic treatment goals that guide an individualized management. The aim of this study is to evaluate the effectiveness of a complex intervention that implements the Ariadne principles in a population of young-old patients with multimorbidity and polypharmacy. The intervention seeks to improve the appropriateness of prescribing in primary care (PC), as measured by the medication appropriateness index (MAI) score at 6 and 12months, as compared with usual care. Methods/Design: Design:pragmatic cluster randomized clinical trial. Unit of randomization: family physician (FP). Unit of analysis: patient. Scope: PC health centres in three autonomous communities: Aragon, Madrid, and Andalusia (Spain). Population: patients aged 65-74years with multimorbidity (≥3 chronic diseases) and polypharmacy (≥5 drugs prescribed in ≥3months). Sample size: n=400 (200 per study arm). Intervention: complex intervention based on the implementation of the Ariadne principles with two components: (1) FP training and (2) FP-patient interview. Outcomes: MAI score, health services use, quality of life (Euroqol 5D-5L), pharmacotherapy and adherence to treatment (Morisky-Green, Haynes-Sackett), and clinical and socio-demographic variables. Statistical analysis: primary outcome is the difference in MAI score between T0 and T1 and corresponding 95% confidence interval. Adjustment for confounding factors will be performed by multilevel analysis. All analyses will be carried out in accordance with the intention-to-treat principle. Discussion: It is essential to provide evidence concerning interventions on PC patients with polypharmacy and multimorbidity, conducted in the context of routine clinical practice, and involving young-old patients with significant potential for preventing negative health outcomes. Trial registration: Clinicaltrials.gov, NCT02866799Publisher PDFPeer reviewe

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

Seroprevalence of T. Cruzi infection in blood donors and chagas cardiomyopathy in patients from the coal mining region of coahuila, Mexico

Context and Objective: Chagas disease is considered a worldwide emerging disease; it is endemic in Mexico and the state of Coahuila and is considered of little relevance. The objective of this study was to determine the seroprevalence of T. cruzi infection in blood donors and Chagas cardiomyopathy in patients from the coal mining region of Coahuila, Mexico. Design and Setting: Epidemiological, exploratory and prospective study in a general hospital during the period January to June 2011. Methods: We performed laboratory tests ELISA and indirect hemagglutination in three groups of individuals: 1) asymptomatic voluntary blood donors, 2) patients hospitalized in the cardiology department and 3) patients with dilated cardiomyopathy. Results: There were three levels of seroprevalence: 0.31% in asymptomatic individuals, 1.25% in cardiac patients and in patients with dilated cardiomyopathy in 21.14%. Conclusions: In spite of having detected autochthonous cases of Chagas disease, its importance to local public health remains to be established as well as the details of the dynamics of transmission so that the study is still in progress